S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
15 A.I. Trading Opportunities a Day (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
15 A.I. Trading Opportunities a Day (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
15 A.I. Trading Opportunities a Day (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
15 A.I. Trading Opportunities a Day (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
15 A.I. Trading Opportunities a Day (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
15 A.I. Trading Opportunities a Day (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
15 A.I. Trading Opportunities a Day (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
15 A.I. Trading Opportunities a Day (Ad)
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
NASDAQ:DSGN

Design Therapeutics (DSGN) Stock Forecast, Price & News

$5.76
+0.33 (+6.08%)
(As of 06/2/2023 ET)
Compare
Today's Range
$5.35
$5.78
50-Day Range
$4.99
$7.64
52-Week Range
$4.90
$26.30
Volume
144,986 shs
Average Volume
193,379 shs
Market Capitalization
$322.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.75

Design Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
208.2% Upside
$17.75 Price Target
Short Interest
Bearish
23.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Design Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.66) to ($2.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

726th out of 983 stocks

Pharmaceutical Preparations Industry

364th out of 486 stocks


DSGN stock logo

About Design Therapeutics (NASDAQ:DSGN) Stock

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Receive DSGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DSGN Stock News Headlines

Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
Wedbush Sticks to Its Buy Rating for Design Therapeutics (DSGN)
RBC Capital Keeps Their Buy Rating on Design Therapeutics (DSGN)
See More Headlines

DSGN Price History

DSGN Company Calendar

Last Earnings
3/14/2023
Today
6/04/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DSGN
Fax
N/A
Employees
37
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.75
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+208.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-63,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$5.59 per share

Miscellaneous

Free Float
40,393,000
Market Cap
$322.27 million
Optionable
Not Optionable
Beta
1.21

Key Executives

  • Dr. João Siffert M.D. (Age 60)
    Pres, CEO & Director
    Comp: $993k
  • Dr. Sean Jeffries Ph.D. (Age 43)
    Chief Operating Officer
    Comp: $476k
  • Dr. Aseem Z. Ansari Ph.D.
    Co-Founder & Scientific Advisor
  • Ms. Julie D. Burgess CPA
    Chief Accounting Officer
  • Dr. Elizabeth Gordon Ph.D.
    Sr. VP of Regulatory Affairs
  • Dr. Jae B. Kim FACC (Age 53)
    M.D., Chief Medical Officer
  • Ms. Dawn Giangiulio
    Controller













DSGN Stock - Frequently Asked Questions

Should I buy or sell Design Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DSGN shares.
View DSGN analyst ratings
or view top-rated stocks.

What is Design Therapeutics' stock price forecast for 2023?

4 brokerages have issued 12-month price targets for Design Therapeutics' shares. Their DSGN share price forecasts range from $6.00 to $24.00. On average, they anticipate the company's share price to reach $17.75 in the next year. This suggests a possible upside of 208.2% from the stock's current price.
View analysts price targets for DSGN
or view top-rated stocks among Wall Street analysts.

How have DSGN shares performed in 2023?

Design Therapeutics' stock was trading at $10.26 at the start of the year. Since then, DSGN stock has decreased by 43.9% and is now trading at $5.76.
View the best growth stocks for 2023 here
.

Are investors shorting Design Therapeutics?

Design Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 7,480,000 shares, an increase of 35.5% from the April 30th total of 5,520,000 shares. Based on an average trading volume of 391,100 shares, the days-to-cover ratio is currently 19.1 days. Approximately 23.0% of the shares of the company are short sold.
View Design Therapeutics' Short Interest
.

When is Design Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our DSGN earnings forecast
.

How were Design Therapeutics' earnings last quarter?

Design Therapeutics, Inc. (NASDAQ:DSGN) released its earnings results on Tuesday, March, 14th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.03.

What ETFs hold Design Therapeutics' stock?
When did Design Therapeutics IPO?

(DSGN) raised $228 million in an IPO on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

What is Design Therapeutics' stock symbol?

Design Therapeutics trades on the NASDAQ under the ticker symbol "DSGN."

Who are Design Therapeutics' major shareholders?

Design Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Avoro Capital Advisors LLC (6.26%), BlackRock Inc. (5.69%), FMR LLC (1.71%), Principal Financial Group Inc. (1.29%), State Street Corp (1.27%) and Geode Capital Management LLC (1.13%). Insiders that own company stock include Arsani William, Joao Md Siffert, Rodney W Lappe, Simeon George, Sr One Capital Fund I Aggregat and Stella Xu.
View institutional ownership trends
.

How do I buy shares of Design Therapeutics?

Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Design Therapeutics' stock price today?

One share of DSGN stock can currently be purchased for approximately $5.76.

How much money does Design Therapeutics make?

Design Therapeutics (NASDAQ:DSGN) has a market capitalization of $322.27 million and generates $230,000.00 in revenue each year. The company earns $-63,310,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

How can I contact Design Therapeutics?

Design Therapeutics' mailing address is 6005 HIDDEN VALLEY ROAD SUITE 110, CARLSBAD CA, 92011. The official website for the company is www.designtx.com. The company can be reached via phone at 858-293-4900 or via email at alicia@thrustsc.com.

This page (NASDAQ:DSGN) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -